乙肝病毒携带与非特异性免疫应答机制的关系  

Asymptomatic carrier with non-specific immune response mechanism relations

作　　者：韩祖良 孙渝生[1] 刘英祥[1] 李欣其 王家瑞[1] 

机构地区：[1]黄圃人民医院肝病科,广东中山528429

出　　处：《Journal of US-China Medical Science》2007年第6期32-38,共7页美中医学（英文版）

摘　　要：目的以非特异性主动免疫疗法作为主要研究内容，探讨HBV-DNA和HBeAg睁陆的乙肝病毒携带者（以下简称双阳AsC）与非特异性免疫应答功能及水平低下的关系。方法运用3套治疗方案解决双阳AsC存在的4个环节的连锁治疗问题。结果（1）HBV感染导致非特异性免疫应答功能及水平低下，与HBV-DNA有直接的关系；（2）特异性免疫耐受与AsC治疗及疗效结果的关系，实际反映的是与e抗原的关系，而e抗原虽然是导致AsC抗HBV治疗失败的重要原因，但其呈现的并非是“致命”性的影响作用；（3）AsC与异常免疫以多环节的连锁形式存在。结论解决AsC抗HBV的治疗问题必须建立在非特异性免疫激活药物贯穿应用，抗HBV药物与非特异性免疫激活药物同步联合应用，以及夸导HBV突变成为前C区变异株消除HbeAg的影响作用的基础上。Objective Non-specific immunotherapy initiative as major research content, Discussion HBV-DNA positive and HBeAg positive asymptomatic carder and non-specific immune response function and the low level of the relationship. Methods Three sets of solutions AsC treatment of the four chain link treatment. Results （1） HBV infection constitutes non-specific immune response function and the reasons for the low level, and HBV-DNA has a direct relationship. （2） Specific immune tolerance and AsC treatment and efficacy results, reflect the actual and e antigen, and e antigen is a result AsC anti-HBV treatment of the important reasons for the failure, But his show is not the ＂lethal＂ in effect, and （3） AsC and abnormal immune to the multi-link chain forma. Conclusion The solution to the AsC anti-HBV treatment must be based on non-specific immune activation through drug use anti-HBV drugs with non-specific immune activation synchronous drug combination, and the HBV-induced mutation of the pre-core region variation eliminate HBeAg effect on the basis of wild HBV to have.

关 键 词：双阳AsC 特异性免疫应答功能及水平低下 链式疗法 

分 类 号：R392[医药卫生—免疫学]